Japanese pharmaceutical stocks have reached record highs amid a broader market rally, with the Nikkei 225 index hitting a new peak. Key players like Daiichi Sankyo Co Ltd and UCB Inc. reported significant gains of 4.41% and 342%, respectively. In contrast, technology companies such as Screen Holdings and Lasertec experienced declines. The market’s positive dynamics are fueled by attractive valuations and corporate restructuring, drawing foreign investments away from volatile Chinese markets. Year-to-date, the Nikkei has risen 16.8%, bolstered by strong performances in pharmaceuticals and strong U.S. market indicators, with a majority of Nikkei stocks showing upward progress.